Hiramitsu Heart Clinic, Shiroshita-cho 2-35, Minami-ku, Nagoya 457-0047, Aichi, Japan.
J Cardiol. 2012 Nov;60(5):395-400. doi: 10.1016/j.jjcc.2012.07.010. Epub 2012 Aug 11.
The clinical benefit of ezetimibe, an intestinal cholesterol transporter inhibitor, for treatment of postprandial hyperlipidemia was assessed in subjects who ingested a high-fat and high-glucose test meal to mimic westernized diet.
We enrolled 20 male volunteers who had at least one of the following: waist circumference ≥ 85 cm, body mass index ≥ 25 kg/m(2), or triglycerides (TG) from 150 to 400mg/dL. After 4 weeks of treatment with ezetimibe (10mg/day), the subjects ingested a high-fat and high-glucose meal. Then changes in serum lipid and glucose levels were monitored after 0, 2, 4, and 6h, and the area under the curve (AUC) was calculated for the change in each parameter.
At 4 and 6h postprandially, TG levels were decreased (p<0.01) after 4 weeks of ezetimibe treatment, and the AUC for TG was also decreased (p<0.01). Apolipoprotein B48 (apo-B48) levels at 4 and 6h postprandially were significantly decreased after ezetimibe treatment (p<0.01 and p<0.001, respectively), and the AUC for apo-B48 was also significantly decreased (p<0.01). Blood glucose and insulin levels at 2h postprandially were significantly decreased by ezetimibe (p<0.05). The AUCs for blood glucose and insulin were also significantly decreased (p<0.05 and p<0.01, respectively). Since ezetimibe improved postprandial lipid and glucose metabolism, this drug is likely to be beneficial for dyslipidemia in patients with postprandial metabolic abnormalities.
评估肠道胆固醇转运蛋白抑制剂依折麦布对进餐后高脂血症的临床疗效，研究采用高脂高糖测试餐模拟西方饮食。
纳入 20 名男性志愿者，至少符合以下标准之一：腰围≥85cm、体重指数≥25kg/m2 或甘油三酯 150-400mg/dL。给予依折麦布（10mg/天）治疗 4 周后，受试者进高脂高糖餐。观察 0、2、4、6h 时血清脂质和葡萄糖水平的变化，计算各参数变化的曲线下面积（AUC）。
依折麦布治疗 4 周后，受试者餐后 4、6h 时甘油三酯水平显著降低（p<0.01），甘油三酯 AUC 也显著降低（p<0.01）。餐后 4、6h 时，载脂蛋白 B48（apo-B48）水平明显降低（p<0.01 和 p<0.001），apo-B48 AUC 也明显降低（p<0.01）。餐后 2h 时，血糖和胰岛素水平显著降低（p<0.05），血糖和胰岛素 AUC 也显著降低（p<0.05 和 p<0.01）。依折麦布改善了餐后脂代谢和糖代谢，因此可能有益于餐后代谢异常患者的血脂异常。
